Background: The unavoidable links between the benefits of conventional systemic treatment of cancer and the side effects such as lymphopenia. Objective: To analyze this phenomenon in view of the newly discovered trophic function of circulating hematopoietic stem cells (HSC) and their lymphocyte descendants. Method: We used population statistics and recent current research involving natural aging and preliminary aging with cancer, its cytotoxic therapy, eclampsia at pregnancy, and radiation hormesis. Results: In contrast to immune-defense interpretations of these health conditions, the trophic influence of HSC and morphogenic lymphocytes on natural tissue renewal and regeneration after sublethal injuries eliminates the majority of covered inconsistencies, which are inherent to the dominating idea of cellular immunity. Conclusion: Our examination led to the feeding influence of lymphopoiesis on tumor progression, an indirect mechanism of tumor growth control by systemic therapy via either destruction of trophic cells, or by competitive distraction from malignant tissue via reparation of sublethal injuries in normal tissues. Analyses also involved similarities of the mechanisms of systemic chemotherapy and total body/half body radiotherapy in low doses, as well as the futility of the theoretical opposition of the radiation hormesis phenomenon to the linear non-threshold model, dominant in radiobiology.
Introduction
The concept that the immune system can recognize and eliminate primary de-
Considered Threats to Viability

Aging
The theory of immunology states that aging arises from dysregulation of the immune response to foreign antigens and is associated with acceleration of inflammation followed by natural frailty at the end of life [21] [22] , and during different somatic diseases including cancer [23] . However, a dramatic decline in T-lymphopoiesis of the old people is primarily dependent on the status of progenitor niches in the BM and thymus [24] , which, in turn, become depleted at 40 years of age, with either 100% for the thymus or BM in the lower legs and femurs, or 30% -75% for the BM in bones, sternum, and ribs [25] . The absolute number of circulating CD133+ and CD34+ cells and their clonogenic capacities progressively and significantly decrease with advancing age [26] [27] . Natural exhaustion of lymphopoiesis is responsible for the frailty syndrome and the real senility/aging of the naturally frail population of those ≥75 years of age [28] [29] .
NLR positively correlates with aging in the healthy population [30] , and the ratio increases sufficiently during multiple organ dysfunction syndrome (MODS) [31] [32] due to deadly lymphopenia (lower than 0.5 × 10 9 /L) with concomitant reduced innate γ-δ T cells, which are able to migrate to different epithelial tissues [33] .
Analysis of natural survival curves by age for countries with high social status has shown specific rectangularity of the curve, which arises due to the strongly increasing exponential rate of death (ERD) at the end of life. The younger population (25 -75 years of age) in the US, Sweden, and UK die slowly, with an ERD ≈ 0.0023 -0.0028 per year. ERD in the last 20 -25 years of life for the US population involves an ERD ≈ 0.0812 per year [34] , for Sweden it involves ≈0.102 per year [35] , and for the UK it involves ≈0.146 per year [36] . Such large values of ERD indicate that most of the oldest population (88% -97%) has died in the last 25 years of life. A natural exhaustion of lymphopoiesis and an obvious deficit of trophic cells are more explainable for both MODS and life-threatening multiple organ failures, which also develop during natural frailty, due to poisoning/toxicity, burns, eclampsia, major trauma, and sepsis. leukocytosis and neutrophilia [31] .
Eclampsia
Rapid growth of the fetus during pregnancy, though natural, is associated with complications in 7% of cases, involving preeclampsia with chronic inflammation and with a high risk of death of the mother and the fetus [37] hematopoiesis that was naturally distributed in the population [44] . These data indirectly show the similarity of the temporary status of pregnancy during the originally weakest hemopoiesis with those who experience frailty during natural aging.
Malignancy
A cancer, being embryonic-like tissue, involves a set of conventional cellular processes used to grow the embryo during morphogenesis [45] , as well as to increase the body mass intensively during a young age. In contrast to pregnancy, a malignant growth is an uninterrupted process, which efficiently leads to inflammation, frailty [28] , chronic irreversible lymphopenia, anemia, protein depletion, reduced food intake, fatigue, cachexia, and death [46] [47] [48] . A high number of CD3+ tumor-infiltrating lymphocytes have been widely interpreted as proof of an immune defense against cancer, because they are associated with a favorable prognosis. However, the more lymphocyte infiltration there is, the higher the rate of tumor growth, and the smaller the tumor size and lower stage [49] [50] [51] [52] . This is evidence in favor of a trophic/morphogenic/proliferogenic function of migrating lymphocytes during tumor "vertical" growth, partially involving intertumoral CD34+HSC [6] , which, in turn, shows a positive correlation with the microvascular density of the tumor, involving many intertumoral CD3+ lymphocytes (TILs) and FOXP3+T-regulatory lymphocytes [8] 
The Potentiation of Lymphocytopenia by Both Cancer and Cytotoxic Therapy
Most cancer patients die, losing several decades of their naturally expected life span, despite conventional therapy.
The calculated ERD of all 1.526 million cancer patients diagnosed between 2012 -2016 in the UK for all stages and treated during a 5-year period was 0.143 per year ±0.004 at a confidence interval (CI) of 95% [89] . 
where the x-average age at diagnosis in the subgroups is in years, the y-averaged ERD in the subgroups is in years −1 , with an R-correlation coefficient, and the p-values indicating its validity.
According to Equation (1) 
The Proof for an Indirect Destructive Mechanism of Conventional Systemic Cytotoxic Therapy at the Level of Lymphopoiesis
The well-known increase in malignancy by age is reversed in the oldest cohort of patients. The incidence, mortality, and prevalence of a wide variety of cancer sites (n = 24) stop their increases at approximately 80 years of age, and then decline during the last 25 years to a natural age limit of 105 years. [100] . During aging, the mean rank of death from infectious influenza and pneumonia (J09-J18) increases from 11 (at ages of 45 -79 years) to 7 (at ages of 85 to ≥100 years), manifesting as weakening of the immune system. However, the rank of [103] , and are consistent with in-phase changes of the presence of the CD133 marker in blood and in the process progress of malignancy [104] . As age advances, a dramatic decline in the production of naive T cells has been reported [105] . In contrast to weakening of the lymphoid lineage, myeloid compartmentalization is expanded with aging, providing a proinflammatory environment in the body and becoming detrimental later in life [106] .
Such age-related reduction of cancer activity cannot be explained by the widely accepted explanation that the, "immune system, which fights an infinite number of foreign antigens and breaks down with aging, impairs the body's ability to resist these invaders" [23] . The loss of malignant activity in a naturally sick population relates more realistically to a weakening of the trophic supply, which is common for normal and malignant tissues of a host. limited, and its potency is progressively exhausted by an abnormally high consumption of trophic cells by quasi-embryonic tumors, ceasing trophic passes with the BM. A history of extra consumption of circulating feeding cells for tumor growth before diagnosis is unknown. So, previous weakening of the tropic relation in the "BM-Tumor" limits the opportunity to suppress this mechanism by periodic cytotoxic courses, and predetermines the rate of gradually developing "resistance to therapy" during the clinical period [115] . As a result, initially effective cytotoxic therapy is steadily disabled and even dangerous at later times [80] [84] [86] . A treatment usually continues until it has a chance to work but, in parallel, it exhausts lymphopoiesis from cycle to cycle, losing its effectiveness and inducing serious complications, including incurability and a higher risk of death. Intense chemotherapy can actually shorten the life of patients. People who are much older and have exhausted lymphopoiesis may not be able to tolerate intense treatment, which brings no benefit, despite its intensification [116] .
Thus, the acceleration of aging and frailty by artificial suppression of lymphopoiesis in cancer patients leads to temporary restriction of malignant growth, than "stimulating the immune defense against cancer" at any age. In addition, the deadly "therapeutic" waste of sensitive stem and progenitor cells in the BM decreases its proliferogenic influence on malignant and normal tissues [117] , which explains why the therapeutic benefit of cytotoxic agents is inevitably associated with "moderate" lymphocytopenia [79].
Systemic Therapy Does Not Directly Control the Tumor
The benefit of chemotherapy has been assumed to involve direct lethal activity of the drugs toward tumor cells. However, direct control of tumor growth using local irradiation can be achieved by using only a few dozen Gray (Gy) [118] . Systemic chemotherapy as well as systemic radiotherapy in such huge dose-equivalents would result in the complete ablation of the bone marrow and death of patients.
It is accepted that systemic chemotherapy cannot be lethal for people without cancer as well as nonlethal dose of total body irradiation of a healthy man is not more, than 2 -3 Gy. Then, systemic chemotherapy is unable to kill a tumor cells fundamentally. Moreover, many authors argue that chemotherapy stimulate both the innate and adaptive arms of the immune system [119] . Tumor response to therapy is regulated by its vasculature in range of absorbed doses of radiation not less, than 10 -20 Gy [120] [121] . Thus, nonlethal chemotherapy is not enough to control directly even most sensitive vascular structure of a tumor. The cytotoxic chemotherapy combined with administration of anti-VEGF drugs leads to improvements of survival of patients with colorectal cancer, breast cancer and non-small lung cell cancer compared to chemotherapy alone [122] . In contrast, the results generate some confusion. It is known that the efficacy of chemotherapy depends on efficient delivery of cytotoxic agents to tumor cells through efficient blood flow, whilst antiangiogenic therapy, according to the theory, should destroy blood vessels and thus prevent drug delivery. The confusion eliminates easily, as recruited in tumor microenvironment (TME) mononuclear cells have paradoxical protumor functions. They originate from BM and found in invasive tumor margins and in draining lymphoid organs or lymphoid structures adjacent to TME. TME includes HSC, protumor Treg lymphocytes and B lymphocytes, which convert T into Treg, endothelial cells and pericytes, which promote lymphangiogenesis and cancer progression, including metastases [123] . Inducible "therapeutic" lymphopenia restricts all these protumor activities indirect way. In 1981 we showed, that low-dose irradiation of whole body of tumor-bearing animals except the small shielded area of graft, retards significantly tumor growth and prolongers the life [2] .
The main side effect of conventional systemic chemotherapy or systemic totalor half-body irradiation (TBI or HBI) with repeated low-dose (0. [79] corresponds to acute radiation syndrome (ARS) for healthy people exposed to a single dose of ionizing irradiation of only 2 -4 Gy, followed by precipitously decreasing the total hematopoietic output and probability of death from 5% to 50% [126] [127] . Clinically significant ARS after single TBI in doses as low as 2
Gy classically includes not only hematological but also gastrointestinal, cutaneous, and cardiovascular/central nervous system problems [128] , i.e., the so-called MODS [31] [32]. The post-irradiation MODS is very similar to "complications" after systemic therapy [81] [129] [130] . Nevertheless, the majority of experts insist on "stimulation of anticancer immunity" when treating patients. Thus, they ignore the specific strong deficit of common lymphoid progenitors (CLP)
Lin-CD34+CD38+CD127+ [131] in the BM after ageing [132] and conventional systemic therapy [133] , with an obvious dependence on tumor and metastases progression from the number of intertumoral CD34+HSC [6] , involving a correlation between the microvascular density with the number of intertumoral CD3+, CD3+FOXP3+regs lymphocytes [8] [53].
These data are not compatible with immune explanations, which describe "specific rearrangements on dying tumor cells, which render them visible to the immune system," involving either "replenishment of immune cell pools through its transient lymphodepletion," "subverting tumor-induced immunosuppressive mechanisms," or "exerting direct or indirect stimulatory effects on immune effectors" [134] [135] [136] . A more natural and less controversial suggestion is that the temporal benefit from cytotoxic agents is due to destroying the number of sensitive trophic HSCs and "regulatory" cells. Depending on the treatment agent dose, these trophic cells can not only be destroyed but also distracted from growing cancer cells, resulting from reparation/regeneration of numerous forms of sublethal damage to cells in other normal tissues, in systemically-treated organisms. We call such trophic redistribution a "competitive mechanism" [117] .
The Proof for an Indirect and "Competitive" Mechanism
Even if a cytotoxic factor is insufficient when it comes to diminishing the number of trophic cells, there remains the possibility of distracting them from the growing tumor due to restoring the majority of sublethal injuries of normal cells in exposed neighboring tissues. The phenomenon of radiation hormesis demonstrates this possibility.
Cancer risk is lower in geographic regions with an abnormally high radiation background, which is associated with stimulation of anticancer immune defense by radiation and, hence, with the harmlessness of exposures to low doses [137] [138] [139] [140] [141] . According to this logic, hormesis is supposed to be the missing link to a better cancer treatment [142] . Moreover, "stimulation of im- [149] . The LNT model assumes that radiation damage is directly proportional ("linear") to the doses at all ranges with no safety threshold, so the term "stimulation" contradicts the idea of the total harmfulness of radiation, and is a key part of the current theoretical controversy. However, hormesis could be explained without supposing any stimulation.
Circulating trophic cells take part in tissue reparation and regeneration during adaptive response to low dose cytotoxic stress, which involves enhancement of DNA repair [150] . The changes in an average life span (LS) were compared in a group of whole-life irradiated dogs (a dose 3 mGy/day of Co 60 γ-rays); the weakest animals in the group died first because they were originally more sensitive to irradiation. At the same time, only the weakest animals kept a constant LS after a cumulative dose of 1100 mGy (2700 days vs. the control of 2700 days), while healthier animals (the control of 4300 days), had after irradiation at the same dose a shorter LS of 4050 days [153] . The same cohorts of control and irradiated dogs [data extracted from the γ-Beagle Dog Tissue Archive, hosted by the Woloschak Laboratory (Chicago, IL, USA)] were divided into four subgroups with short and long mean LSs (two control and two irradiated) [154] , and for each of (10-fold). There were no significant differences with controls in both exposed subgroups in terms of the incidence of solid malignancies, metaplasia, inflammation, diarrhea, and vomiting. These data confirmed the tendency of hormesis only in the weakest animals [155] . Because the frailty syndrome correlated with the loss of general somatic health and the loss of body weight [156] , the data exclude the notion that radiation was associated with healing or stimulation and, Therefore, HBI was not be enough for indirect destructive control of tumor growth like chemotherapy did, and should be classified, as "distracting" compared to chemotherapy.
Conclusions
Widely used conventional doses of anticancer drugs as well as TBI/HBI for sys- 
